HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy
Abstract
Genome sequencing has uncovered an array of recurring somatic mutations in different non-Hodgkin lymphoma (NHL) subtypes. If affecting protein-coding regions, such mutations may yield mutation-derived peptides that may be presented by HLA class I proteins and recognized by cytotoxic T cells. A recurring somatic and oncogenic driver mutation of the Toll-like receptor adaptor protein MYD88, Leu265Pro (L265P) was identified in up to 90% of...
Paper Details
Title
HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy
Published Date
Dec 23, 2016
Journal
Volume
6
Issue
3
Pages
e1219825 - e1219825
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History